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Human cytomegalovirus (HCMV) infection has a profound effect on the human immune
system, causing massive clonal expansion of CD8, and to a lesser extend CD4T cells.
The few human trials that have explored the effect of HCMV infection on responses
to vaccination are conflicting, with some studies suggesting no effect whilst others
suggest decreased or increased immune responses. Recent studies indicate substantial
differences in overall immune system reactivity to vaccines based on age and sex,
particularly cellular immunity. 225 nine-month old Gambian infants were immunized
with diphtheria-tetanus-whole cell pertussis and/or measles vaccines. HCMV infection
status was determined by the presence of CMV DNA by PCR of urine samples prior
to vaccination. The effect of HCMV infection on either protective antibody immunity
or vaccine-specific and overall cellular immune responses 4 weeks post-vaccination
was determined, further stratified by sex. Tetanus toxoid-specific antibody responses
were significantly lower in HCMV+ infants compared to their HCMV- counterparts,
while pertussis, diphtheria and measles antibody responses were generally comparable
between the groups. Responses to general T cell stimulation with anti-CD3/anti-CD28
as well as antigen-specific cytokine responses to purified protein derivative (PPD) were
broadly suppressed in infants infected with HCMV but, perhaps surprisingly, there was
only a minimal impact on antigen-specific cellular responses to vaccine antigens. There
was evidence for subtle sex differences in the effects of HCMV infection, in keeping
with the emerging evidence suggesting sex differences in homeostatic immunity and in
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responses to vaccines. This study reassuringly suggests that the high rates of HCMV
infection in low income settings have little clinically significant impact on antibody
and cellular responses to early life vaccines, while confirming the importance of sex
stratification in such studies.
Keywords: human cytomegalovirus, human infants, measles vaccination, diphtheria-tetanus-pertussis (DTwP)
vaccination, vaccine responses, antibodies, cellular immunity
INTRODUCTION
Human cytomegalovirus (HCMV) is a highly prevalent herpes
virus (human herpes virus 5) that leads to lifelong chronic
latent infection in humans once it is acquired. Latent infection
is generally asymptomatic although symptomatic reactivation
can occur, particularly in the immunocompromised or pregnant
host (1, 2). The overall global prevalence is estimated at 83%,
approaching 100% in developing countries (3) but closer to 66%
in Europe (4). It tends to be acquired in adult life in developed
countries while the epidemiology is quite different in resource
poor settings where the majority of children will be infected
before their first birthday (5).
HCMV infection is known to cause amassive clonal expansion
of the CD8+ T cell population in adults (6) and children (5),
and a lesser but still considerable expansion of CD4+ T cells
in both adults and children (7) leading to inversion of the
normal CD4:CD8 ratio to <1. The expanded T cells are typically
terminally differentiated, as indicated by their lack of expression
of CD27 and CD28 and positive expression of CD57 (5, 8). The
combination of chronic HCMV infection, late-differentiated T
cells and inverted CD4:CD8T cell ratio and are all components
of an “immune risk profile” (IRP) that has been associated with
immunosenescence, cognitive decline, frailty and early death
in the elderly (9–13). However, not all studies support these
associations, for example HCMV infection was not associated
with frailty in the largest longitudinal study conducted in the
elderly to date (Newcastle 85+ Study) (14) and the IRP is not
consistent across all populations studied and varies according to
biological sex (15). Systemic inflammation, characterized by high
serum levels of C reactive protein (CRP), tumor necrosis factor
alpha (TNF-α) and interleukin 6 (IL-6), is also part of the IRP. It
has been proposed that HCMV infection drives the inflammation
associated with aging, so called “inflammaging” (16), but other
studies refute such an association (17).
There is some weak evidence that HCMV infection may
impair antibody responses to influenza vaccination in the elderly
(18), but the studies are inconsistent and inconclusive and this
question is yet to be resolved (19–21). A study of 263 18–52
year olds found no effect of HCMV infection on responses to
a H1N1 pandemic influenza vaccine (22), while another found
significantly lower responses in the HCMV+ as compared to the
HCMV- cohort (18). Influenza vaccinated HCMV seropositive
individuals >65 years of age had impaired in vitro inducible
granzyme B release to influenza virus, but there was no apparent
effect on antibody responses to standard titer or high titer
influenza vaccination according to HCMV status (23). A systems
biology analysis of younger (20–30 years) and older (60–>89
years) individuals found enhanced antibody responses following
influenza vaccination in the HCMV+ healthy young adults
compared to the HCMV- younger individuals (24). By contrast,
the older adults had poorer responses to vaccination regardless of
HCMV status. In the same study, murine CMV infected young
mice were better protected against influenza challenge than their
uninfected counterparts. Taken together this would suggest that
HCMV enhances immunity in young healthy individuals.
A Gambian study showed that HCMV+ infants had
similar antibody responses to measles, tetanus and Haemophilus
influenzae b (Hib) vaccination at 13 and 18 months of age
as compared to their HCMV- counterparts; and while they
had lower CD4+ IFN-γ responses to measles 1 week after
vaccination, there was no effect on measles-specific immunity 4
months post-vaccination (8). The HCMV+ infants did however
have greater proliferation to polyclonal T cell stimulation
with staphylococcal enterotoxin B, supporting enhanced cellular
immunity in the HCMV infected children (8). Another study
in 178 Gambian infants found that HCMV infection had
no effect on antibody responses 2 months after measles and
meningococcus A and C vaccination at 9 months of age (25).
In the same study, EBV infection was associated with lower
responses to all three vaccine antigens, and HCMV co-infection
negated this negative effect on measles but not meningococcal
antibody responses. This suggests a beneficial immunological
effect of HCMV infection on T cell-dependent but not the T cell-
independent vaccines (25). Similarly, a more recent longitudinal
study of healthy children at 2, 5 and 10 years of age showed that
EBV but not HCMV infection was associated with an accelerated
decline in rubella and measles-specific IgG levels (26).
The effect of high rates of HCMV infection in infants
in resource poor settings undergoing routine vaccination is
therefore still not clear. Herein, we analyzed the effect of HCMV
infection on antibody and cellular responses to diphtheria,
tetanus-whole cell pertussis (DTP) vaccine and measles vaccine
(MV) in a prospective study of 302 Gambian infants. Due to the
well-described sex differences in immunity (27, 28) and vaccine
responses (29) and the large cohort size and well-defined nature
of the participants in this study, we were further able for the
first time to analyse the effect of the infant’s biological sex on the
above parameters, with the aim of shedding light into potentially
contradictory previous results.
MATERIALS AND METHODS
Study Cohort and Vaccines Given
This is a sub-study nested within a randomized trial investigating
the immunological effects of vaccination with diphtheria-
tetanus-whole cell pertussis (DTP) vaccine, measles vaccine
(MV) or both vaccines given together to 9 month old infant
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TABLE 1 | Study design including vaccines given from birth and infant numbers by HCMV status and sex.
Age MV group MV+DTP group DTP group
Birth BCG/OPV/HBV BCG/OPV/HBV BCG/OPV/HBV
1m OPV OPV OPV
2m DTP1/Hib/OPV/HBV DTP1/Hib/OPV/HBV DTP1/Hib/OPV/HBV
3m DTP2/Hib/OPV DTP2/Hib/OPV DTP2/Hib/OPV
4m DTP3/Hib/OPV/HBV Hib/OPV/HBV Hib/OPV/HBV
9m Blood sample, Urine for HCMV Blood sample, Urine for HCMV Blood sample, Urine for HCMV
MV (n = 82) MV+DTP3 (n = 90) DTP3 (n = 53)





































10m Blood sample, Urine for HCMV Blood sample, Urine for HCMV Blood sample, Urine for HCMV





































Infants were recruited at 4 months of age and randomized to one of the 3 vaccine groups: The MV group received their normal 4 month vaccines and MV alone at 9 months; the other 2
groups had DTP3 delayed and either given with MV at 9 months (MV+DTP group) or given alone (DTP group). All infants received their recommended vaccines from birth. At 9 and 10
months of age blood samples were taken for antibody and cellular assays and urine tested for HCMV by PCR. The number of HCMV+ and HCMV- infants at 9 and 10 months are shown
by sex and the percentage values indicate the percent HCMV- or HCMV+ in that vaccine group for males (M), females (F) or all infants combined (All). BCG, bacille Calmette-Guérin
vaccine; OPV, oral polio vaccine; HBV, hepatitis B vaccine; DTP, diphtheria-tetanus-whole cell pertussis vaccine; Hib, Haemophilus influenzae type b vaccine. The bold letters indicate
the vaccine interventions in the study protocol.
Gambians, the primary findings of which have been published
previously (30, 31). We investigated the effect of HCMV
infection on responses to the two vaccines. The main study
recruited 302 four-month old infants presenting for routine
vaccination at Sukuta Health Center, a peri-urban area 20 km
from the coast of The Gambia. Eligibility criteria required that
the child was healthy, had no history of chronic illness, no
fever (<37.5◦C), normal weight-for-age, and up to date with
all recommended vaccines according to the national Expanded
Program on Immunization (EPI) schedule. HIV status was not
determined but the adult prevalence at the time of the study
was low, estimated at between 1 and 4%, and would therefore
be extremely low in these infants (5). Infants were randomized
into one of three vaccine groups which determined the vaccines
to be given at 9 months of age: Group 1 received a single
standard intramuscular (i.m.) MV (Edmonston Zagreb strain,
Serum Institute of India Ltd., Pune, India); group 2 received MV
and i.m. DTP in two different sites (Serum Institute of India Ltd.);
and group 3 received DTP alone (Table 1). Males and females
were randomized separately. Groups 2 and 3 had their third dose
of DTP withheld at 4 months to be given at 9 months, whereas
group 1 received it as normal. All three groups received oral polio
vaccine (OPV) and Haemophilus influenza b vaccine (Hib) at 4
months of age as recommended by the EPI. A 4.5mL sample
of venous blood was collected into a heparinised tube (7.5 units
heparin/mL) at 9 months immediately prior to vaccination and
4 weeks later (median 28 days, interquartile range 28–29 days).
Of the 302 infants recruited at 4 months, 286 received the study
vaccine intervention at 9 months of age and 254 returned for
follow-up at 10 months of age. Of these, 225 who had HCMV
results and vaccine antibody and/or cytokine data are included in
this sub-study (Table 1).
Ethics Statement
The study protocol was approved by the Joint Gambia
Government/MRC Ethics Committee (project number
SCC1085) and the London School of Hygiene and Tropical
Medicine Ethics Committee. Written/thumb-printed informed
consent was provided by a parent/guardian of all participating
infants in accordance with the Declaration of Helsinki.
Diagnosis of HCMV Infection
The infants were too young for serum HCMV IgG testing due
to likely persistence of maternally-derived antibody. Therefore,
urine samples were collected at 9 and 10 months of age and
tested for the presence of HCMV DNA by a nested polymerase
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chain reaction (PCR) with a cut off of approximately 25 DNA
copies/mL, as previously described (32, 33). Appropriate positive
and negative controls were employed to reduce the likelihood of
false positive diagnoses. Furthermore, infants that tested positive
at 9 months were all confirmed to be positive at 10 months
and are thus likely true positives since urinary secretion usually
persists for at least 6 months post-infection. Urine was not
available for all donors and only those with a result at 9 months
of age are included in this study.
Vaccine Antibody Assays
Heparinised whole blood was spun at 2,000 rpm for 5min
and plasma collected and stored at −70◦C. The measles IgG
haemagglutination inhibition assay (HAI) was performed using
monkey red blood cells as previously described (34). Results
are expressed as log2 units, the minimum detection level being
31.2mIU, and a protective level defined as ≥125mIU (log2 titer
≥3). A multiplex microsphere based fluorescent immunoassay
for IgG antibodies to diphtheria toxoid (Dtx), tetanus toxoid
(Ttx) and four pertussis antigens [pertussis toxoid (Ptx), fimbriae
(Fim), filamentous haemagglutinin (FHA) and pertactin (Per)]
was performed at the National Institute of Public Health and the
Environment (RIVM), Netherlands using published protocols
(35). Vaccine-induced IgG levels for Dtx and Ttx require a post-
vaccination titer of ≥0.1 international units (IU)/mL for long-
term protection, although lower levels of 0.01–0.1 IU/mL may
provide some protection. There are no established protective
levels for the pertussis antibodies.
FIGURE 1 | Vaccine antibodies 4 weeks after vaccination according to
baseline HCMV status. Antibody titres to the vaccine antigens measured 4
weeks after vaccination (infants aged 10 months) according to HCMV status
on the day of vaccination. The antibody titer values are shown on a logarithmic
scale and each symbol represents an individual infant. The horizontal bar
indicates the median value. Only significant adjusted p-values are shown in the
figure indicating lower Ttx antibodies in HCMV+ as compared to HCMV-
infants. Ttx, tetanus toxoid; Dtx, diphtheria toxoid; Ptx, pertussis toxoidl; FHA,
filamaentous haemagglutinin; Prn, pertactin; Fim, fimbriae; MV, measles virus.
Whole Blood Cultures and Cytokine
Multiplex Analysis
In addition to vaccine-specific cell mediated immune (CMI)
responses, we also analyzed for reactivity to the unrelated antigen
PPD and the general T cell stimulant anti-CD3/anti-CD28.
100µL aliquots of heparinized whole blood were cultured in
96-well U-bottom plates with a measles peptide-pool of 122
15mer peptides overlapping by 10 amino acids spanning the
immunodominant measles haemagglutinin protein (all 1µg/mL
final concentration, Sigma-Genosys, UK); tetanus toxoid (TT
antigen) (10µg/ml, Sanofi Pasteur, France); purified protein
derivative (PPD) (10µg/mL, Statens Serum Institute, Denmark);
anti-CD3 (αCD3) (5µg/mL, Becton-Dickinson (BD), USA) and
anti-CD28 (αCD28) (5µg/mL, eBiosciences, UK); and medium
alone as a negative control. Plates were incubated for 16 h at 37◦C,
5% CO2, centrifuged at 2,000 rpm for 5min and supernatant
collected and stored at−20◦C.
Cytokine concentrations were analyzed in thawed culture
supernatants using a customized 10-plex array [interleukin
1 beta [IL-1β], IL-4, interferon-gamma [IFN-γ], IL-10, IL-
12(p70), eotaxin, granulocyte macrophage colony-stimulating
factor [GM-CSF], platelet derived growth factor-BB [PDGF-
BB], tumor necrosis factor [TNF], vascular endothelial growth
factor [VEGF]] acquired using the Bio-Plex 200 Suspension
Array system (Bio-Rad, Hercules, California, USA) as described
previously (30). This panel was selected based on preliminary
assays showing that these 10 cytokines/chemokines were
differentially affected in the different vaccine groups. Pro-
inflammatory to anti-inflammatory cytokine ratios were also
analyzed to gain further insights into the effect of HCMV
infection on the immune homeostatic response (36). Since TNF
and IFN-γ are pivotal pro-inflammatory cytokines and IL-10
is a key anti-inflammatory cytokine we analyzed the IFN-γ:IL-
4 ratio as an indication of the T helper 1 (Th1):Th2 balance
and the TNF:IL-10 and IFN-y:IL-10 ratios. Assays were not
performed for all infants due to insufficient blood volume, clotted
or contaminated blood samples. Thus, 147 of the 225 infants
included in the study had cytokine results (MV group n = 50,
DTP group n= 55, MV+DTP group n= 42).
Statistical Analysis
General linear modeling was used to estimate the geometric
mean, geometric standard deviation (GSD), mean difference,
95% confidence interval and p-value for each variable for the
different subject groups (infants with and without HCMV
infection, different vaccine groups, males, and females). The
effects of infant sex and vaccine groups were determined by
estimating HCMV:sex interactions and HCMV:vaccine group
interactions. Analysis was performed on natural logarithmic
transformed antibody levels then converted back to natural
numbers by exponential transformation; thus, the GSD is a
multiplicative factor, and not an absolute value. Since univariate
analysis is unlikely to capture the complex inter-relationships
between the immune parameters tested, multivariate linear
regression modeling was used. Infant sex, HCMV status and
immune parameters (all other antibody results for antibody data
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TABLE 2 | Effect of HCMV infection on vaccine antibody measurements.
HCMV– HCMV+ Comparison1 (unadjusted) Comparison1 (adjusted) 2
N Geo mean N Geo mean 1 95%CI P-value 1 95%CI P-value
(GSD) (GSD)
Ttx 39 5.73 (2.10) 104 3.43 (2.72) −2.29 (−3.19 to −1.08) 0.001 −1.44 (−2.20 to −0.49) 0.005
Dtx 39 1.13 (3.02) 104 0.83 (3.40) −0.30 (−0.59 to 0.12) 0.14 0.03 (−0.22 to 0.38) 0.82
Ptx 39 26.4 (6.4) 104 28.9 (7.5) 2.5 (−11.9 to 31.5) 0.80 10.9 (−5.1 to 43.0) 0.24
Fim 39 654 (4.0) 104 448 (3.0) −206 (−376 to 66) 0.12 −86 (−235 to 134) 0.39
FHA 39 132 (3.5) 104 83 (3.2) −49 (−79 to −2) 0.044 −14 (−39 to 22) 0.40
Prn 39 126.5 (3.5) 104 85.9 (3.6) −40.6 (−72.2 to 9.4) 0.098 1.7 (−29.9 to 48.7) 0.93
MV 56 145 (8.9) 108 260 (9.1) 115 (−17 to 383) 0.11 147 (−21 to 507) 0.11
Vaccine antibodies were measured 4 weeks after vaccination at 9 months of age. Ptx, Dtx, Ttx, Fim23, FHA and Prn were measured in the DTP and MV+DTP groups only, while MV was
measured in the MV and MV+DTP groups only. 1Estimated using general linear modeling. P < 0.05 are indicated in bold type. 2Covariates selected for adjustment by forward stepwise
regression. N, number of infants analyzed; Geo mean, geometric mean; GSD, geometric standard deviation;∆, mean difference; 95% CI, 95% confidence interval; Dtx, diphtheria toxoid;
Ttx, tetanus toxoid; Ptx, pertussis toxoid; FHA, filamaentous haemagglutinin; Prn, pertactin; Fim, fimbriae; MV, measles virus.
TABLE 3 | HCMV infection does not significantly affect protective antibody levels.
Vaccine antibody Protective Below threshold (N) Above threshold (N) Fisher’s exact test
Threshold value HCMV– HCMV+ HCMV– HCMV+ P-value
Dtx antibodies ≥0.1 IU/mL 1 3 38 101 1.0
Ttx antibodies ≥0.1 IU/mL 0 1 39 103 1.0
Measles antibodies ≥3 log2 titer 5 9 51 99 1.0
Number of infants above and below the post-vaccination protective threshold antibody levels according to HCMV status. N, number of infants; Dtx, diphtheria toxoid; Ttx, tetanus toxoid.
and all other cytokine/chemokine values for CMI data) were
considered potential covariates for adjustment. Those covariates
selected by forward stepwise regression had an entry p-value of
0.15 and a removal p-value of 0.2 and were presented to the
statistical model as z-scores of the natural logarithms of the raw
values. Missing data were substituted by multiple imputation
(using “mi estimate: glm” Stata syntax, with 50 imputations).
Results are presented as unadjusted and adjusted for covariates,
but only adjusted p-values are reported in the text unless
otherwise stated. Fisher’s exact tests were used to analyse the
proportion of HCMV+ and HCMV– infants with antibody levels
above and below the protective threshold. All statistical analyses




The infant characteristics at 9 months of age have been described
elsewhere for this cohort of children (30, 31). HCMV status
was determined for 225 infants (108 females and 117 males)
at 9 months of age for whom we had paired blood samples at
10 months of age, among whom 153 (68%) were found to be
HCMV+ and 72 (32%) were HCMV– (Table 1). An equivalent
proportion ofmales and females wereHCMV+: 77 (71.3%) of the
108 females and 76 (65%) of the 117 males (Chi-square= 1.04, p
= 0.31). More than half (46/72, 63.9%) of the HCMV– infants at
9 months of age had acquired the infection by the 10 months of
age, resulting in an 88% HCMV infection rate by this age.
HCMV Infection Is Associated With Lower
Tetanus IgG Responses Following DTP
Vaccination
There was no significant difference in measles HAI geometric
mean titres between the HCMV+ and HCMV- infants who
received measles vaccination (p = 0.11) (Figure 1, Table 2). By
contrast, the HCMV+ infants who received a DTP vaccination
at 9 months of age (with or without MV) had lower tetanus
toxoid IgG titres (p = 0.005) than the HCMV- individuals, while
IgG responses to diphtheria toxoid and the 4 pertussis antigens
(pertussis toxoid, pertactin, FHA, and fimbriae) did not appear to
be significantly influenced by HCMV status (Figure 1, Table 2).
Importantly, the presence of HCMV infection did not affect
the proportion of donors achieving protective antibody levels
to Ttx, Dtx or measles vaccination (Table 3) but this could not
be analyzed for pertussis antigens for which protective levels
have not been established. An analysis for the effect of sex
similarly showed that Ttx IgG responses were significantly lower
in DTP vaccinated HCMV+ males (p = 0.017), but the lower
levels in HCMV+ females were only significant on unadjusted
analysis (unadjusted p = 0.038, adjusted p = 0.13). Pertactin
IgG responses were also lower in HCMV+ females compared
to the uninfected females on unadjusted analysis (p = 0.033)
but not after adjustment for covariables (p = 0.22), while IgG
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TABLE 4 | Effect of HCMV infection on cytokine responses to T cell stimulation with aCD3/CD28 at 9 months of age.
HCMV– HCMV+ Comparison1 (unadjusted) Comparison1 (adjusted) 2
N Geo mean N Geo mean 1 95%CI P-value 1 95%CI P-value
(GSD) (GSD)
IL-4 48 18.7 (2.5) 98 10.2 (4.2) −8.6 (−11.8 to −3.9) 0.002 −2.5 (−4.4 to −0.1) 0.046
IL-1β 48 2584 (11) 98 1204 (15) −1380 (−2072 to 250) 0.080 −27 (−452 to 561) 0.92
IL-10 48 1481 (8.1) 98 1090 (8.4) −391 (−952 to 763) 0.41 299 (−19 to 719) 0.068
IL-12(p70) 48 99 (2.7) 98 99 (3.5) 0 (−31 to 45) 0.99 8 (−10 to 29) 0.41
Eotaxin 48 268 (2.9) 98 169 (3.5) −99 (−153 to −19) 0.020 −7 (−47 to 43) 0.76
GMCSF 48 23.6 (12.7) 98 14.8 (11.5) −8.9 (−17.4 to 11.3) 0.28 −5.8 (−14.2 to 12.5) 0.42
IFN-γ 48 2810 (5.8) 98 1939 (8.2) −871 (−1794 to 889) 0.26 185 (−559 to 1296) 0.68
PDGFBB 48 8617 (2.5) 98 8776 (2.0) 159 (−2042 to 3097) 0.90 520 (−1378 to 2932) 0.62
TNF 48 4402 (16.3) 98 1162 (32.1) −3240 (−3992 to −1107) 0.012 −565 (−1109 to 251) 0.15
VEGF 48 639 (2.6) 98 607 (4.1) −32 (−228 to 257) 0.80 −35 (−135 to 86) 0.55
TNF/IL-10 48 2.97 (4.25) 98 1.07 (6.68) −1.91 (−2.36 to −1.12) <0.001 −0.53 (−1.00 to 0.20) 0.13
IFN-γ/IL-10 48 3.95 (4.52) 98 4.80 (4.67) 0.85 (−1.10 to 4.14) 0.46 0.78 (−1.17 to 4.07) 0.51
IFN-γ/IL-4 48 150 (4.8) 98 191 (4.1) 41 (−37 to 171) 0.37 30 (−34 to 125) 0.41
Analysis by Sex
IL-4
Male 24 20.1 (2.3) 47 9.6 (4.9) −10.4 (−14.5 to −3.3) 0.009 −3.7 (−6.4 to −0.3) 0.035
Female 24 17.5 (2.7) 51 10.7 (3.7) −6.8 (−11.2 to 0.6) 0.067 −1.2 (−4.2 to 2.7) 0.51
Eotaxin
Male 24 256 (3.2) 47 194 (4.3) −61 (−151 to 106) 0.39 49 (−16 to 141) 0.16
Female 24 281 (2.5) 51 149 (2.9) −132 (−188 to −44) 0.007 −59 (−103 to 0) 0.049
TNF
Male 24 4624 (18.8) 47 809 (35.0) −3816 (−4450 to −881) 0.026 −1333 (−1862 to −393) 0.011
Female 24 4189 (15.0) 51 1622 (29.7) −2567 (−3793 to 2453) 0.187 274 (−633 to 1839) 0.63
TNF/IL-10 0.046
Male 24 2.89 (4.37) 47 0.85 (7.88) −2.04 (−2.52 to −0.95) 0.004 −0.94 (−1.43 to −0.04) 0.043
Female 24 3.06 (4.27) 51 1.31 (5.62) −1.75 (−2.43 to −0.31) 0.025 −0.07 (−0.84 to 1.36) 0.90
Whole blood was cultured with aCD3/aCD28 and cytokines measured by multiplex assay in the culture supernatants after 18 h of culture. 1Estimated using general linear modeling. P
<0.05 are indicated in bold type. 2Covariates selected for adjustment by forward stepwise regression as described in methods. Only those cytokines which showed significant effects
of HCMV infection in the sex analysis are shown. N, number of infants analyzed; Geo mean, geometric mean; GSD, geometric standard deviation; ∆, mean difference; 95% CI, 95%
confidence interval.
responses to all other vaccine antigens were comparable in males
and females with or without HCMV (Supplementary Table 1).
Analysis was also performed separately for the individual
vaccine groups to see if the dual administration of MV with
DTP influenced the effect of HCMV for each vaccine antigen
(Supplementary Table 1). This showed that the HCMV+ infants
in the MV+DTP group had lower Ttx titres (p = 0.012)
compared to HCMV– infants, whereas the effect was only
significant in the DTP alone group on unadjusted but not
adjusted analysis (p = 0.19). While not the case for the DTP
and MV+DTP infants combined, Dtx IgG levels were lower
in HCMV+ infants who received DTP alone on unadjusted
analysis (<0.001) but not after adjusting for other variables
(p = 0.22). The same applied to unadjusted analysis of IgG
responses to Fim, FHA and Pertactin which were significantly
lower in HCMV+ individuals in the DTP (p = 0.031, p
= 0.05, p = 0.003, respectively) but not those that received
DTP+MV, and not significant after adjusting for other variables
(Supplementary Table 1).
Suppressed Overall T Cell and PPD
Reactivity in HCMV Infected Infants
Stimulation of infant whole blood with anti-CD3 plus anti-
CD28 was performed to analyse overall non-antigen specific T
cell reactivity at baseline (Table 4). Univariate analysis showed
a significantly lower IL-4 (p = 0.002), TNF (p = 0.012),
eotaxin (p = 0.02), and TNF:IL-10 ratio (p < 0.0001) in culture
supernatants from HCMV infected as compared to HCMV
uninfected infants, but only IL-4 was significant on adjusting
for covariates (p = 0.046). Responses to the mycobacterial
antigen purified protein derivative (PPD) were also generally
suppressed in those infected with HCMV as evidenced by lower
unadjusted PPD-stimulated IL-4 (p = 0.025), IL-1β (p = 0.039),
eotaxin (p = 0.003), GMCSF (p = 0.036), TNF (p = 0.021),
and TNF:IL-10 ratio (p = 0.004) in the HCMV+ compared
to the HCMV– group, of which only GMCSF (p = 0.021)
was significant after multivariate adjustment, and IL-12(p70)
(p = 0.035) and IL-10 (p = 0.044) were also significant after
adjusting (Table 4). Of note, the unstimulated cytokine levels
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TABLE 5 | Effect of HCMV infection on cytokine responses to PPD at 9 months of age.
HCMV– HCMV+ Comparison1 (unadjusted) Comparison1 (adjusted) 2
N Geo mean N Geo mean 1 95%CI P-value 1 95%CI P-value
(GSD) (GSD)
IL-4 48 12.2 (4.1) 98 7.0 (4.0) −5.2 (−7.9 to −0.8) 0.025 −1.8 (−4.3 to 2.0) 0.31
IL-1β 48 1245 (11) 98 515 (11) −730 (−1022 to −55) 0.039 4 (−195 to 282) 0.98
IL-10 48 739 (6.5) 98 569 (5.8) −171 (−437 to 329) 0.41 186 (4 to 432) 0.044
IL-12(p70) 48 76.3 (3.2) 98 74.1 (4.7) −2.2 (−28.9 to 39.7) 0.90 16.1 (1.0 to 34.6) 0.035
Eotaxin 48 229 (3.1) 98 117 (4.8) −113 (−155 to −47) 0.003 −50 (−97 to 23) 0.15
GMCSF 48 21.7 (13.0) 98 8.5 (12.4) −13.2 (−18.2 to −1.3) 0.036 −13.8 (−18.5 to −3.0) 0.021
IFN-γ 48 2951 (5.5) 98 2730 (5.1) −221 (−1417 to 1907) 0.79 1023 (−78 to 2705) 0.073
PDGFBB 48 7417 (2.5) 98 6060 (2.2) −1357 (−2953 to 811) 0.20 −352 (−1617 to 1227) 0.63
TNF 48 1336 (18) 98 409 (19) −926 (−1186 to −219) 0.021 −144 (−342 to 163) 0.30
VEGF 48 523 (3.0) 98 429 (3.5) −94 (−234 to 115) 0.33 −69 (−140 to 17) 0.11
TNF/IL-10 48 1.81 (6.19) 98 0.72 (6.62) −1.09 (−1.42 to −0.45) 0.004 −0.37 (−0.71 to 0.18) 0.16
IFN-γ/IL-10 48 3.95 (4.52) 98 4.80 (4.67) 0.85 (−1.10 to 4.14) 0.46 0.78 (−1.17 to 4.07) 0.51
IFN-γ/IL-4 48 241 (5.6) 98 388 (4.0) 148 (−18 to 436) 0.091 165 (−9 to 479) 0.069
Analysis by Sex
GMCSF
Male 24 16.0 (14.3) 47 7.8 (13.6) −8.2 (−13.9 to 12.2) 0.27 −7.7 (−12.1 to 7.4) 0.20
Female 24 29.5 (12.0) 51 9.2 (11.6) −20.3 (−26.7 to 0.5) 0.053 −23.6 (−30.9 to −3.5) 0.030
TNF/IL-10
Male 24 1.92 (6.07) 47 0.67 (7.25) −1.25 (−1.65 to −0.27) 0.023 −0.63 (−0.93 to −0.07) 0.033
Female 24 1.69 (6.55) 51 0.77 (6.16) −0.93 (−1.38 to 0.17) 0.081 −0.02 (−0.62 to 1.24) 0.97
Whole blood was cultured with PPD and cytokines measured by multiplex assay in the culture supernatants after 18 h of culture. 1Estimated using general linear modeling. P < 0.05
are indicated in bold type. 2Covariates selected for adjustment by forward stepwise regression as described in methods. Only those cytokines which showed significant effects of
HCMV infection in the sex analysis are shown. N, number of infants analyzed; Geo mean, geometric mean; GSD, geometric standard deviation; ∆, mean difference; 95% CI, 95%
confidence interval.
in whole blood supernatants were unaffected by HCMV status
(Supplementary Table 2).
When analyzing separately by sex the lower reactivity in
the HCMV+ infants compared to the HCMV- group was
also apparent but only significant in one sex or the other.
Thus, HCMV+ males but not females had significantly lower
aCD3aCD28 stimulated IL-4 (p = 0.035), TNF (p = 0.011), and
TNF:IL-10 (p = 0.043); while HCMV+ females but not males
had lower aCD3aCD28 stimulated eotaxin (p = 0.049) than
their HCMV– counterparts (Table 4). PPD reactivity showed
a similar pattern with HCMV+ males having lower PPD-
stimulated TNF:IL-10 ratios (p = 0.033); and females but
not males having lower PPD-stimulated GMCSF (p = 0.003)
(Table 5).
Minimal Effect of HCMV Infection on
Vaccine-Specific Cellular Reactivity to
Vaccination
Whole blood collected 4 weeks after vaccination was stimulated
overnight with a measles peptide pool to determine measles-
specific cellular reactivity in infants who received a measles
vaccine (MV and MV+DTP groups), and responses to tetanus
toxoid (TT antigen) were analyzed in infants who received a
DTP vaccine (DTP and MV+DTP groups). Analysis for the
impact of HCMV infection on the day of vaccination on the
subsequent in vitro cytokine responses to the vaccine antigens
showed very little consequence of HCMV infection on responses
to measles vaccination, with only VEGF responses being lower
(p = 0.002) in the HCMV+ compared to HCMV- infants
(Table 6). Analysis separately in males and females showed that
HCMV+ males had higher measles-specific IL-12(p70) (p =
0.024) and lower VEGF (p = 0.003) than the HCMV– males;
while HCMV+ females had higher measles-specific GMCSF than
their uninfected counterparts (p = 0.04) (Table 6). When the
MV and MV+DTP groups were analyzed separately the measles
stimulated eotaxin (p = 0.017) and VEGF (p = 0.016) were
both lower in the HCMV+MV+DTP group, but not those who
received MV alone (Supplementary Table 3).
Among the infants who received a DTP vaccine, there was
a significantly lower TT-stimulated GMCF (p = 0.009) and
eotaxin (P = 0.001) response among those infected with HCMV
compared to the uninfected cohort (Table 6). Analysis in the
individual sexes showed that HCMV infected females had higher
IL-1β (p = 0.025), TNF (p = 0.014), and PDGFBB (p = 0.05)
in TT cultures whereas males had lower GMCSF (p = 0.013)
(Table 7). Analysis of the MV+DTP and DTP groups separately
showed that the MV+DTP group had significantly lower IL-1β
(p= 0.03), and higher eotaxin (p= 0.035) and TNF responses to
TT (p = 0.005) among HCMV infected infants while the DTP
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TABLE 6 | Effect of baseline HCMV status on measles-specific cytokine responses 4 weeks after vaccination.
CMV– CMV+ Comparison1 (unadjusted) Comparison1 (adjusted) 2
N Geo mean N Geo mean 1 95%CI P-value 1 95%CI P-value
(GSD) (GSD)
IL-4 33 4.72 (4.80) 72 5.91 (4.82) 1.19 (−1.58 to 6.41) 0.49 −0.31 (−1.60 to 1.49) 0.70
IL-1β 33 274 (24.1) 72 389 (28.8) 115 (−169 to 1163) 0.60 22 (−64 to 160) 0.67
IL-10 33 141 (14) 72 175 (9) 33 (−77 to 334) 0.68 −15 (−50 to 38) 0.53
IL-12(p70) 33 43.3 (6.4) 72 56.5 (4.4) 13.3 (−15.2 to 70.9) 0.46 21.8 (0.1 to 54.6) 0.049
Eotaxin 33 183 (5.9) 72 259 (5.0) 76 (−54 to 335) 0.33 −8 (−84 to 113) 0.87
GMCSF 33 2.38 (21.7) 72 5.17 (17.9) 2.79 (−0.85 to 15.1) 0.21 1.00 (−0.46 to 4.09) 0.24
IFN-γ 33 1411 (4.8) 72 1862 (6.3) 451 (−456 to 2219) 0.42 −144 (−587 to 521) 0.62
PDGFBB 33 5199 (2.7) 72 6819 (2.8) 1620 (−637 to 4994) 0.19 1743 (−207 to 4489) 0.086
TNF 33 174 (27) 72 306 (24) 132 (−91 to 960) 0.40 27 (−43 to 144) 0.52
VEGF 33 373 (4.9) 72 220 (9.8) −153 (−268 to 87) 0.16 −210 (−282 to −94) 0.002
TNF/IL-10 33 1.23 (4.35) 72 1.71 (5.77) 0.48 (−0.32 to 1.99) 0.30 0.14 (−0.43 to 1.12) 0.69
IFN-γ/IL-10 33 9.98 (6.06) 72 10.5 (5.54) 0.55 (−4.82 to 11.5) 0.88 2.07 (−3.58 to 12.4) 0.56
IFN-γ/IL-4 33 299 (3.5) 72 317 (4.2) 18 (−111 to 237) 0.82 −9 (−129 to 191) 0.91
Analysis by Sex
IL-12(p70)
Male 17 41.6 (5.1) 31 51.3 (4.7) 9.7 (−20.8 to 84.8) 0.65 34.6 (3.3 to 92.1) 0.024
Female 16 45.2 (8.5) 41 61.2 (4.2) 16.0 (−25.0 to 140) 0.59 7.3 (−17.3 to 48.6) 0.63
GMCSF
Male 17 5.52 (31.0) 31 3.55 (15.0) −1.97 (−4.93 to 16.0) 0.63 −0.43 (−1.79 to 3.68) 0.74
Female 16 0.93 (10.8) 41 7.00 (20.4) 6.07 (0.70 to 29.2) 0.007 2.33 (0.06 to 8.71) 0.040
VEGF
Male 17 476 (3.7) 31 156 (14.0) −320 (−423 to −22) 0.041 −302 (−379 to −143) 0.003
Female 16 283 (6.4) 41 290 (6.9) 6 (−183 to 553) 0.97 −119 (−223 to 69) 0.17
Whole blood was cultured with a measles peptide pool (results for measles vaccinated infants only shown) and cytokines measured by multiplex assay in the culture supernatants after
18 h of culture. 1Estimated using general linear modeling. P < 0.05 are indicated in bold type. 2Covariates selected for adjustment by forward stepwise regression as described in
methods. Only those cytokines which showed significant effects of HCMV infection in the sex analysis are shown. N, number of infants analyzed; Geo mean, geometric mean; GSD,
geometric standard deviation; ∆, mean difference; 95% CI, 95% confidence interval.
alone group showed no significant effect of HCMV infection
(Supplementary Table 3).
CONCLUSIONS
As expected, a high incidence of HCMV infection was found in
this Gambian infant cohort, reaching 88% by 10 months of age
(5). Previous studies of the impact of HCMV infection on vaccine
responses have variously described decreased, unaffected and
enhanced antibody responses in the elderly; while the handful
of early life studies have shown no effect on antibody responses
to measles, rubella, meningococcus A and C, tetanus and Hib
(25). The present study largely suggests minimal effects of HCMV
infection on antibody responses to vaccination with diphtheria-
tetanus-whole cell pertussis vaccine or measles vaccine at 9
months of age. Indeed, only Ttx titres were convincingly lower
in infants infected with HCMV compared to the uninfected
infants, while measles HAI titres and responses to four pertussis
antigens and diphtheria toxoid were not affected by HCMV
status. Analysis in the individual sexes confirmed significantly
lower Ttx IgG levels in HCMV+ males but the lower levels in
HCMV+ females were not significantly different to HCMV–
females, probably due to lower numbers when analyzing the
sexes separately. Thus, there was little evidence for sex differential
effects of HCMV infection on antibody responses in our study.
These lower Ttx titres are unlikely to be of major significance
since HCMV+ infants still generally had levels well above the
protective threshold. There is a suggestion that vaccination with
DTP alone led to lower levels to other vaccine antigens—Dtx,
Fim, FHA and Pertactin—in the HCMV+ infants but not when
MV was given with DTP suggesting a boosting effect of MV
co-administration, but this observation was only significant on
unadjusted analysis. The live vaccine bacille Calmette-Guérin
has similarly been shown to boost antibody responses to co-
administered vaccines (37, 38).
HCMV infection is known to lead to expansion of terminally
differentiated T cells, particularly in the CD8T cell subset (5).
One might therefore predict that this would impact cellular
responses to vaccination, although this has not been investigated
except for the one study showing an early decline in measles-
specific CD4T cell IFN-γ responses in HCMV infected infants
(8). We found little evidence for a major impact of HMCV
infection on vaccine-induced cellular immunity to measles or
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TABLE 7 | Effect of baseline HCMV status on TT-specific cytokine responses 4 weeks after vaccination.
CMV– CMV+ Comparison1 (unadjusted) Comparison1 (adjusted) 2
N Geo mean N Geo mean 1 95%CI P-value 1 95%CI P-value
(GSD) (GSD)
IL-4 28 6.66 (3.48) 68 7.86 (4.13) 1.21 (−2.16 to 7.10) 0.56 0.09 (−1.16 to 1.72) 0.90
IL-1β 28 750 (22) 68 716 (23) −34 (−560 to 1947) 0.95 −99 (−215 to 141) 0.32
IL-10 28 202 (10) 68 405 (12) 204 (−55 to 917) 0.18 30 (−36 to 134) 0.44
IL-12(p70) 28 32.2 (5.8) 68 50.1 (5.3) 17.9 (−8.4 to 73.4) 0.24 11.8 (−9.3 to 46.2) 0.33
Eotaxin 28 90 (5.3) 68 202 (4.9) 112 (9 to 319) 0.026 53 (−5 to 149) 0.078
GMCSF 28 44.5 (12.1) 68 24.8 (22.5) −19.6 (−36.7 to 34.7) 0.33 −11.9 (−17.3 to −0.9) 0.038
IFN-γ 28 1259 (4.6) 68 1603 (7.1) 344 (−476 to 2023) 0.51 −296 (−655 to 274) 0.26
PDGFBB 28 9002 (2.9) 68 10096 (4.8) 1094 (−3065 to 8166) 0.67 52 (−3149 to 5126) 0.98
TNF 28 352 (11) 68 781 (21) 429 (−99 to 2066) 0.17 137 (−5 to 403) 0.063
VEGF 28 216 (8.0) 68 246 (8.4) 31 (−116 to 390) 0.77 −19 (−101 to 115) 0.73
TNF/IL-10 28 1.75 (4.91) 68 1.90 (4.16) 0.15 (−0.77 to 1.93) 0.81 0.24 (−0.54 to 1.77) 0.63
IFN-γ/IL-10 28 6.24 (5.88) 68 3.94 (4.60) −2.30 (−4.34 to 1.93) 0.22 −1.98 (−4.34 to 2.25) 0.29
IFN-γ/IL-4 28 199 (3.6) 68 204 (3.2) 5 (−80 to 149) 0.93 10 (−73 to 154) 0.86
Analysis by Sex
IL-1β
Male 11 652 (28) 33 516 (36) −136 (−594 to 3919) 0.83 145 (−100 to 892) 0.37
Female 17 827 (19) 35 984 (14) 157 (−632 to 4122) 0.83 −225 (−303 to −42) 0.025
GMCSF
Male 11 48.7 (16.6) 33 11.8 (25.4) −36.9 (−46.9 to 28.6) 0.14 −23.1 (−28.4 to −7.9) 0.013
Female 17 41.7 (9.5) 35 51.1 (17.4) 9.4 (−29.1 to 166) 0.78 −3.5 (−12.3 to 18.5) 0.64
PDGFBB
Male 11 12605 (2.4) 33 6252 (7.2) −6353 (−9853 to 1597) 0.094 −5892 (−9785 to 2420) 0.13
Female 17 7098 (3.0) 35 16081 (2.2) 8983 (1906 to 21624) 0.006 3871 (2 to 10097) 0.050
TNF
Male 11 365 (10) 33 358 (27) −7 (−298 to 1552) 0.98 44 (−103 to 459) 0.68
Female 17 343 (13) 35 1667 (14) 1324 (40 to 6899) 0.035 234 (32 to 639) 0.014
Whole blood was cultured with tetanus toxoid for those infants vaccinated with DTP (DTP and MV+DTP groups) and cytokines measured by multiplex assay in the culture supernatants
after 18 h of culture. 1Estimated using general linear modeling. P < 0.05 are indicated in bold type. 2Covariates selected for adjustment by forward stepwise regression as described
in methods. Only those cytokines which showed significant effects of HCMV infection in the sex analysis are shown. N, number of infants analyzed; Geo mean, geometric mean; GSD,
geometric standard deviation; ∆, mean difference; 95% CI, 95% confidence interval.
DTP vaccination. This is interesting because HCMV infection
seemed to lead to lower pro-inflammatory (TNF, IL1β, eotaxin,
GMCSF) and Th2 (IL-4) reactivity to general T cell stimulation
and the mycobacterial antigen PPD as compared to the HCMV-
infants. The lower responses in HCMV+ infants were apparent
in both males and females but involved different cytokine profiles
in the sexes: TNF and the Th2 cytokine IL-4 for males and
the innate cytokines eotaxin and GMCSF for females. When
analyzing measles-specific immunity, the only cytokine response
apparently affected by HCMV infection was the growth factor
VEGF, which was lower in HCMV+ infants. The lack of impact
of HCMV infection on measles-specific innate pro-inflammatory
cytokines IL-1β and TNF, the Th1 cytokine IFN-γ, the Th2
cytokine IL-4 and the anti-inflammatory cytokine IL-10 is
encouraging. The clinical significance of lower VEGF production
is uncertain but it is an important vascular growth factor that has
also been linked with trauma and malignancy (39, 40). Effects on
tetanus toxoid-specific responses similarly showed lower GMCSF
and eotaxin in the HCMV+ infants but no effect on innate
pro-inflammatory, Th1, Th2 cytokines or IL-10.
HCMV+ males exhibited higher measles-specific IL-12(p70)
production, while females had higher measles-specific GMCF
and higher TT-cultured pro-inflammatory innate cytokines
(IL-1β and TNF) and PDGFBB as compared to their HCMV-
counterparts. This suggests that HCMV infection may have
a greater enhancing effect on vaccine-specific cell mediated
immunity in females, with mixed effects among males. The
finding of sex differences in HCMV effects are consistent with
the recent studies showing sex differences in immunological
responses to vaccination (28, 29).More robust immune responses
in females as compared to males have been reported in the
vaccine literature, but sex differences in the immunological
consequences of HCMV infection have not previously been
described. Differences in sex hormone levels in infant males and
females and the multiple X-linked immune response genes have
been implicated mechanistically in sex-differential immunity but
have yet to be confirmed as the cause. Sex differences in the gut
microbiota may also play a role (41) given the studies suggesting
that the microbiota influences vaccine-specific immunity (42).
Furthermore, non-human primate studies suggest that latent
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HCMV infection alters the gut microbiota composition, which
the authors propose could lead to heterogeneity in responses to
vaccines (43), although this has not been studied in humans.
Several limitations of this study should be borne in mind.
One is that some infants who acquired HCMV early in life may
no longer be shedding virus in their urine by 9 months of age.
However, previous longitudinal studies of HCMV carriage from
birth suggest that viral shedding is quite persistent in early life
(44) and that only a minority of those infected earlier will test
negative at 9 months of age (5). Also, many of those infants
who were HCMV negative at 9 months of age had become
positive by 10 months of age when the vaccine responses were
measured. Since it is not possible to determine at what point they
became positive we have to accept that HCMV acquisition shortly
after vaccination could also have had an effect on responses to
vaccination and interfered with our results.
We therefore find little evidence that the very high levels
of HCMV infection in African infants has a major impact
of vaccine-specific immunity despite the profound polyclonal
expansion and terminal differentiation of their T cells. This is in
keeping with the existing limited studies but would suggest that
almost universal HCMV infection by 1 year of age in many low-
income countries does not prevent them responding adequately
to vaccination. From an evolutionary point of view this is a good
strategy for this highly successful virus that is able to establish
life-long latent infection from an early age. Indeed, the opinion
is now swaying to consider HCMV infection beneficial to the
immune system in younger years, whilst becoming detrimental
in older individuals (45). This study, in combination with those
already published, should therefore alleviate any concerns that
early HCMV infection significantly diminishes vaccine induced
protective immunity, even when consideration of sex is taken
into account.
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